Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.

Not Applicable

Completed

Conditions: Myocardial Infarction
Multivessel Coronary Artery Disease

Registration Number: NCT01399736

Lead Sponsor: Maasstad Hospital

Brief Summary: The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction. The purpose of the study is to compare a FFR guided multivessel PCI taking place during the primary PCI with a primary PCI of the culprit vessel only.

Patients will be enrolled after successful revascularisation of the culprit vessel. Patients that have at least one lesion with a diameter of stenosis of more than 50% on visual estimation, feasible (operators judgement) for treatment with PCI in a non-infarct related artery, will be randomised either to the FFR guided complete revascularisation arm or staged revascularisation by proven ischemia or persistence of symptoms of angina.

Approximately 885 patients will be entered in the study.

Study hypothesis: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines.

Detailed Description: Background of the study: At the moment the general opinion is divided over the way the non culprit lesions in patients presenting with STEMI should be treated. While the previous guidelines stead that these lesions should be treated in a second time ( ie not during the primary intervention) the actual guidelines do not touch this argument. The reason is that the studies where the previous guidelines were based are old. Meanwhile small sized randomised trials from EU region have proven favourable outcomes with NON infarct related artery during the primary procedure while registers (non randomised trials) from USA still recommend the staged treatment. For this reason we have decided to perform a randomised study to address this issue incorporating the state of the art diagnosis and treatment, as well as the new medical therapy and PCI techniques.

Objective of the study: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines

Study design: Prospective, 1: 2 randomisation. FFR guided revascularisation during primary PCI (1) versus following actual guidelines (2)

Study population: All STEMI patients between 18-85 years who will be treated with primary PCI in \< 12 h (more than 12 hr if persisting pain allowed) after the onset of symptoms and have at least one stenosis of \>50% in a non-IRA judged feasible for treatment with PCI.

Intervention (if applicable): FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines

Primary study parameters/outcome of the study: Composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Stroke (MACCE) at 12 months

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 885

Inclusion Criteria

All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in < 12 h after the onset of symptoms* and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.
- Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised

Exclusion Criteria

Left main stem disease (stenosis > 50%)
STEMI due to in-stent thrombosis
Chronic total occlusion of a non-IRA
Severe stenosis with TIMI flow ≤ II of the non-IRA artery.
Non-IRA stenosis not amenable for PCI treatment (operators decision)
Complicated IRA treatment, with one or more of the following;
- Extravasation,
- Permanent no re-flow after IRA treatment (TIMI flow 0-1),
- Inability to implant a stent
Known severe cardiac valve dysfunction that will require surgery in the follow-up period.
Killip class III or IV already at presentation or at the completion of culprit lesion treatment.
Life expectancy of < 2 years.
Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy.
Gastrointestinal or genitourinary bleeding within the prior 3 months,
Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
Pregnancy or planning to become pregnant any time after enrolment into this study.
Inability to obtain informed consent.
Expected lost to follow-up.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Number of Participants With Death From Any Cause	12 months	Number of participants with all cause mortality at 12 months between groups
Number of Participants With Spontaneous MI	12 months	Number of participants with Spontaneous Myocardial Infarction at 12 months between groups
Number of Participants With the Composite Endpoint of MACCE	12 months	Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups
Number of Participants With Revascularization - CABG	12 months	Number of participants with revascularization CABG at 12 months between groups
Number of Participants With Periprocedural MI	12 months	Number of participants with Periprocedural Myocardial Infarction at 12 months between groups
Number of Participants With Cerebrovascular Event	12 months	Number of participants with Cerebrovascular event at 12 months between groups
Number of Participants With Revascularization - PCI	12 months	Number of participants with revascularization PCI at 12 months between groups
Number of Participants With Cardiac Death	12 months	Number of participants with Cardiac mortality at 12 months between groups

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Death From Any Cause or MI	3 year	Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year
Number of Participants With Major Bleeding	12 months	Number of participants with Major bleeding at 12 months - Part of composite NACE
Number of Participants With Any Bleeding at 12 Months	12 months	Number of participants with any bleeding at 12 months - part of composite endpoint NACE
Number of Participants With Any Bleeding at 48 Hours	48 hours	Number of participants with any bleeding at 48 hours - part of composite endpoint NACE
Number of Participants With Revascularization	12 months	Number of participants with any revascularization-Part of composite endpoint NACE
Number of Participants With Elective Revascularization at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation
Number of Participants With Any Bleeding at 3 Year	3 year	Number of participants with any bleeding at 3 year - Part of composite endpoint NACE
Number of Participants With Hospitalization	3 year	Number of participants with Hospitalization for heart failure, unstable angina, MI
Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year	3 year	Number of participants with Composite primary endpoint MACCE (any first event) at 3 year
Number of Participants With All Cause Death at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death
Number of Participants With Peri-procedural MI at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI
Number of Participants With Major Bleeding at 3 Year	3 year	Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year
Number of Participants With Stent Thrombosis at 3 Year	3 year	Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE
Number of Participants With Composite Endpoint of NACE (Any First Event)	12 months	Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e. Net Adverse Clinical Events)
Number of Participants With Cardiac Death at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death
Number of Participants With Cerebrovascular Event	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event
Number of Participants With Hospitalization at 3 Year	3 year	Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain
Number of Participants With Stent Thrombosis	12 months	Number of participants with Stent Thrombosis - Part of composite endpoint NACE
Number of Participants With Urgent Revascularization at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation
Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year	3 years	Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e. Net Adverse Clinical Events)
Number of Participants With Spontaneous MI at 3 Year	3 year	Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI

Trial Locations

Locations (26): University Hospital BRNO
🇨🇿
Brno, Czechia
University Hospital Hradec Králové
🇨🇿
Hradec Králové, Czechia
Liberec Regional Hospital
🇨🇿
Liberec, Czechia
Herz-Zentrum Bad Krozingen
🇩🇪
Bad Krozingen, Germany
Herzzentrum Bad Segeberger Klinik
🇩🇪
Bad Segeberg, Germany
Klinikum Links der Weser
🇩🇪
Bremen, Germany
Medizinische Klinik IV
🇩🇪
Ingolstadt, Germany
Medical University Rostock
🇩🇪
Rostock, Germany
Gottsegen György Országos Kardiológiai Intézet
🇭🇺
Budapest, Hungary
Szabolcs - Szatmár - Bereg County Hospitals and University Teaching Hospital
🇭🇺
Nyíregyháza, Hungary
Scroll for more (16 remaining)
University Hospital BRNO
🇨🇿Brno, Czechia